Image

Effect of NMN (Nicotinamide Mononucleotide) on Polycystic Ovary Syndrome

Effect of NMN (Nicotinamide Mononucleotide) on Polycystic Ovary Syndrome

Not Recruiting
20-40 years
Female
Phase N/A

Powered by AI

Overview

The purpose of the study is to understand the effect of Nicotinamide mononucleotide (NMN) on patients with polycystic ovary syndrome.

Description

This study aims to evaluate the effects of NMN on reproductive endocrine and metabolism, chronic inflammation, and reproductive outcomes in women with polycystic ovary syndrome (PCOS), and to explore its underlying mechanisms to provide the intervention strategies for PCOS.

Eligibility

Inclusion Criteria:

  1. Individuals who are 20 to 40 years old, planning to become pregnant or infertile women.
  2. Individuals who are diagnosed as PCOS according to the revised 2003 Rotterdam diagnostic criteria: if 2 out of 3 criteria are met: 1) Oligo- and/or anovulation; 2) Clinical and/or biochemical signs of hyperandrogenism; 3) Polycystic ovaries, and exclusion of other aetiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome).
  3. Individuals who can insist on continuous monitoring in the outpatient clinic.
  4. Individuals who are not participating in other research projects currently or 3 months before the intervention.

Exclusion Criteria:

  1. Individuals who suffering from other diseases that may cause hyperandrogenism and ovulation abnormalities.
  2. Individuals who are during pregnant, lactation or menopause.
  3. Individuals who currently receiving weight-loss drugs or surgery or within the past 2 months.
  4. Individuals who take niacin, nicotinamide, or other vitamin B3-related supplementation currently or within the past 2 months.
  5. Individuals who need regular medication to treat chronic diseases such as diabetes, hypertension, gout, hyperuricemia, etc.
  6. Use of medications that affect hormone levels, appetite, carbohydrate absorption, and metabolism within the past 2 months.
  7. Individuals with severe liver diseases or kidney disease that are ineligible to participate in the study.
  8. A medical history of severe cardiovascular and cerebrovascular diseases.
  9. Individuals who currently suffer from severe gastrointestinal diseases or undergo gastrointestinal resection that may affect nutrient absorption.
  10. Individuals who drink more than 15g of alcohol per day or have a smoking habit.
  11. Individuals who need drug treatment for any mental illness such as epilepsy and depression.
  12. Cancer patients.
  13. Individuals who suffer from infectious diseases such as hepatitis B, active tuberculosis, AIDS, etc.

Study details
    Polycystic Ovary Syndrome

NCT05305677

Peking University Third Hospital

12 December 2025

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.